Adaptive Biotechnologies : Fourth Quarter and FY 2020 Earning Conference Call

Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward -looking statements are neither historical facts nor

assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,

our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "p otential," "continue," "ongoing" or the negative of these terms or

other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to COVID-19, Lyme disease, Crohn's disease or other disease state, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious disea ses; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and pro spective products and product candidates, including clonoSEQ, immunoSEQ T-MAP COVID and T-Detect products, discovery and development of neutralizing antibodies and their expected efficacy with respect to SARS-CoV-2 and other disease states, FDA approval or authorization of any products, including our EUA application for T-Detect COVID; planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of our anticipated product candidates; the availability of alternative t herapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management' s Discussion and Analysis of Financial Condition

and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Annual Report on Form 10-K filed on February 24, 2021. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those exp ressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data ob tained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliabilit y of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Significant progress in 2020

• ◼ Strong revenue growth despite COVID impact:

  • ❑ Q4'20 $30.2M (+25% y/y)

  • ❑ FY'20 $98.4M (+16%y/y)

• ◼ Successful follow-on offering with strong B/S

❑

~$807M in cash, cash equivalents and marketable securities as of 12/31/2020

• ◼ Completed data package for 1st shared product to enable IND filing by GNE

• ◼ Identified several neutralizing antibodies that strongly bind to different parts of SARS-CoV-2 at low concentrations

• ◼ Launched T-Detect COVID and filed with FDA

• ◼ T-Detect pipeline: immuneSENSE study for Lyme initiated; identified Crohn's disease signal

• ◼ clonoSEQ CLL clearance in blood and bone marrow; successful launch

• ◼ Filed clonoSEQ for ALL in blood with FDA

• ◼ Launched immunoSEQ T-MAP COVID for vaccine developers

• ◼ Signed agreement with AztraZeneca to use immunoSEQ T-MAP in AZ's cancer portfolio

• ◼ immunoSEQ RUO kit: signed agreements with 2 CRO's (Q2; Labcorp) & 35 core labs and user groups

We translate the genetics of the immune system into clinical products

"One" Immune Medicine

PlatformSynergistic Data Interplay

Immune Medicine Products

Commercial Products

Pipeline Products

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical summary.

T-Detect™ is an IVD for prescription use only. This test has not been cleared or approved by the FDA. The T-Detect COVID Assay is available for use as a CLIA-validated laboratory developed test (LDT). immunoSEQ® and immunoSEQ® T-MAP™ COVID are for Research Use Only. Not for use in diagnostic procedures.